Opdivo will keep growing, Bristol-Myers says, trying to talk investors off the ledge
It’s no secret that Bristol-Myers Squibb’s investors are feeling skittish after a pair of negative Opdivo developments last week. And on Thursday’s third-quarter conference call, executives plunged right into their doubts. After a two-day period in which the company 1) saw competitive kidney cancer data posted by Opdivo archrival Keytruda from Merck and 2) produced… Read More »